Skip to Content
Diagnosed with psoriatic arthritis? Learn about biologics >>

Salicylic Acid

Class: Keratolytic Agents
ATC Class: D01AE12
VA Class: DE500
CAS Number: 69-72-7
Brands: AcneFree, Ambi, Aveeno, ClarityMD, Clean and Clear, Clearasil, Compound W, Denorex, Dermarest, DHS Sal, Dr. Scholl’s, DuoFilm, Gordofilm, Hydrisalic, Keralyt, Kerasal, Mediplast, MG217, Neutrogena, Noxzema, Oxy, Paraid, Proactiv, Psoriasin, Salactic, Salex, Sal-Plant, Sebasorb, Stridex, UltraSal-ER, Virasal

Introduction

Keratolytic agent; derivative of benzoic acid.a

Uses for Salicylic Acid

Acne

Used topically for the management of acne.100 104 105 113 114 115 118 119 125 126

Seborrheic Dermatitis, Psoriasis, and Dandruff

Used topically to control seborrheic dermatitis of the body and scalp, psoriasis of the body and scalp, and dandruff.103 109 121 127

Hyperkeratosis

Used topically for its keratolytic effect in the removal of common and plantar warts,101 106 107 111 112 116 122 123 corns, and calluses.102 110 112

Salicylic acid 5% in fixed-combination with urea 10% is used to soften and control growth of calluses.108

Do not use on moles, birthmarks, warts with hair(s) growing from them, genital warts, or warts on the face or mucous membranes.101 106 116

Also used topically for management of other hyperkeratotic skin disorders such as ichthyoses vulgaris, palmoplantar keratosis, pityriasis rubra pilaris, and keratosis pilaris.117

Salicylic Acid Dosage and Administration

General

  • Salicylic acid is commercially available in various preparations, some of which are intended for self-medication; consult manufacturer’s labeling for complete directions for appropriate dosage and administration of specific products.100 101 102 103

Administration

Topical Administration

Apply topically to the skin as a cake, cream, gel, lotion, ointment, pledget, plaster, shampoo, solution, or suspension.104 105 106 107 108 109 110 111 112 113 114 115 116 117

For external use only.100 101 102 103 Avoid contact with the eyes; if contact occurs, flush thoroughly with water.101 102 103

Acne

For self-medication, apply topically using appropriate preparation containing salicylic acid 0.5–2%.100 104 105 113 114 115

Cleanse and dry the affected area prior to topical application.100

If using a product that is intended to be applied and removed (e.g., cleanser, soap, mask, scrub), rinse thoroughly with water after application.100 104 105

Seborrheic Dermatitis, Psoriasis, and Dandruff

For self-medication, apply topically using appropriate preparation containing salicylic acid 1.8–3% to affected areas of skin and/or scalp.103 109

Apply preparations formulated as soaps or shampoos to affected area(s) in place of regular soap or shampoo.103 109

Corn and Callus Removal

For self-medication, apply topically using appropriate preparation containing salicylic acid 12–40% (in plaster) or 12–17.6% (in collodion-like vehicle).102

Cleanse and dry affected area prior to topical application.102 May soak affected area(s) in warm water for 5 minutes to aid in removal of the corn or callus.102

If using a plaster product, trim plaster (if necessary) to fit over the callus or corn.102

If using a product in a collodion-like vehicle, apply small amount (e.g., one drop at a time) with an applicator to sufficiently cover corn or callus and allow to dry.102

Kerasal foot ointment (salicylic acid 5% in combination with urea 10%): Gently massage into skin until fully absorbed.108 For faster results, apply in the evening and cover skin with cotton socks after application.108

Do not apply on irritated, reddened, or infected areas.102

Wart Removal

For self-medication, apply topically using appropriate preparation containing salicylic acid 12–40% (in plaster), 5–17% (in collodion-like vehicle), or 15% (in karaya gum-glycol plaster vehicle).101

Cleanse and dry affected area prior to topical application; may soak affected area(s) in warm water for 5 minutes.101

If using a plaster preparation, trim to fit (if necessary).101 112

If using a preparation in collodion-like vehicle, apply small amount (e.g., one drop at a time) with an applicator to sufficiently cover wart; allow to dry.101 107 111

If using a preparation in karaya gum-glycol plaster, gently smooth wart surface with emery file and apply a drop of warm water to wart prior to application; keep surrounding skin dry.101 Apply plaster at bedtime.101

Salicylic acid 27.5 or 28.5% solution: Prior to application, soak wart in warm water for 5 minutes.106 116 Remove any loose tissue by gently rubbing (e.g., with a wash cloth, emery board, or brush); dry thoroughly.106 116 Use brush applicator supplied by manufacturer to apply solution; allow to dry.106 116

Apply only to wart site and not on surrounding normal skin.106 116 Do not apply on irritated, reddened, or infected areas.101

Dosage

Pediatric Patients

Acne
Topical

Self-medication using a 0.5–2% preparation intended to be applied and left on the skin (e.g., gel, lotion): Apply a thin layer 1–3 times daily.100 114 115 To reduce risk of excessive skin dryness, initially apply once daily, then gradually increase to 2–3 times daily as necessary or directed by clinician.100 114 If bothersome dryness or peeling occurs, reduce application to once daily or every other day.100 114

Self-medication using a 0.5–2% preparation intended to be applied and removed from the skin (e.g., cleansers, soaps, masks, scrubs): Apply a thin layer to affected area and rinse thoroughly 1–3 times daily.100 104 105 To reduce risk of excessive skin dryness, initially apply once daily, then gradually increase to 2–3 times daily as necessary or directed by clinician.100 104 If bothersome dryness or peeling occurs, reduce application to once daily or every other day.100 104 105

Self-medication using a 0.5–2% solution-containing pledget (pad): Wipe affected area with 1 pad; may repeat with a clean pad if necessary to remove remaining traces of dirt.113 To reduce risk of excessive skin dryness, initially apply once daily, then gradually increase to 2–3 times daily as necessary or directed by clinician.113 If bothersome dryness or peeling occurs, reduce application to once daily or every other day.113

Hyperkeratosis
Hyperkeratotic Skin Disorders (verrucae, ichthyoses vulgaris, palmoplantar keratosis, keratosis pilaris, pityriasis rubra pilaris, psoriasis [including body, scalp, palms, and soles])
Topical

Salicylic acid 6% cream or lotion in children ≥2 years of age: Hydrate affected area of skin (e.g., with wet packs or baths) for ≥5 minutes prior to application.117 Apply topically to affected area(s) at bedtime and occlude.117 Wash off in the morning; may apply a bland cream or lotion if affected skin is irritated or excessively dry.117 In areas where occlusion is not possible, apply more frequently.117 However, excessive, repeated application does not necessarily increase therapeutic benefit and may increase risk of adverse local effects and salicylism.117 (See Salicylate Toxicity under Cautions.)

Adults

Acne
Topical

Self-medication using a 0.5–2% preparation intended to be applied and left on the skin (e.g., gel, lotion): Apply a thin layer 1–3 times daily.100 114 115 To reduce risk of excessive skin dryness, initially apply once daily, then gradually increase to 2–3 times daily as necessary or directed by clinician.100 114 If bothersome dryness or peeling occurs, reduce application to once daily or every other day.100 114

Self-medication using a 0.5–2% preparation intended to be applied and removed from the skin (e.g., cleansers, soaps, masks, scrubs): Apply a thin layer to affected area and rinse thoroughly 1–3 times daily.100 104 105 To reduce risk of excessive skin dryness, initially apply once daily, then gradually increase to 2–3 times daily as necessary or directed by clinician.100 104 If bothersome dryness or peeling occurs, reduce application to once daily or every other day.100 104 105

Self-medication using a 0.5–2% solution-containing pledget (pad): Wipe affected area with 1 pad; may repeat with a clean pad if necessary to remove remaining traces of dirt.113 To reduce risk of excessive skin dryness, initially apply once daily, then gradually increase to 2–3 times daily as necessary or directed by clinician.113 If bothersome dryness or peeling occurs, reduce application to once daily or every other day.113

Seborrheic Dermatitis, Psoriasis, and Dandruff
Skin and Scalp
Topical

Self-medication using a 1.8–3% salicylic acid cream, ointment, or lotion: Apply to affected area(s) 1–4 times daily or as directed by clinician.103

Self-medication using a 1.8–3% salicylic acid shampoo: Apply to wet skin and/or scalp and massage to form a lather.103 109 Leave lather on for several minutes, then rinse thoroughly; repeat if necessary.103 109 For best results, use at least twice weekly or as directed by clinician.103 109

Hyperkeratosis
Corn or Callus Removal
Topical

Self-medication using a 12–40% salicylic acid plaster: Apply to corn or callus for 48 hours.102 112 After 48 hours, remove plaster.102 112 Repeat every 48 hours as needed (for up to 14 days) until corn or callus is removed.102 112 If discomfort persists, consult clinician.102

Self-medication using a 12–17.6% salicylic acid solution or gel in collodion: Apply small amount (e.g., 1 drop at a time) to sufficiently cover corn or callus.102 110 Repeat once or twice daily as needed for up to 14 days.102 110 If discomfort persists, consult clinician.102

Kerasal foot ointment (salicylic acid 5% in combination with urea 10%): Apply sparingly to calloused skin once daily to soften and prevent growth of calluses.108 Response may be seen as early as 2-3 days.108

Wart Removal
Topical

Self-medication using a 12–40% salicylic acid plaster: Apply to wart for 48 hours.101 Repeat every 48 hours as needed for up to 12 weeks until wart is removed.101

Self-medication using a 5–17% salicylic acid solution or gel in flexible collodion-like vehicle: Apply small amount (e.g., 1 drop at a time) to sufficiently cover wart.101 111 Repeat once or twice daily for up to 12 weeks until wart is removed.101 111

Self-medication using a 15% salicylic acid plaster in a karaya gum and glycol vehicle: Apply to wart at bedtime; leave in place for ≥8 hours, then remove and discard.101 Repeat every 24 hours as needed for up to 12 weeks until wart is removed.101

Salicylic acid 27.5 or 28.5% solution (e.g., UltraSal-ER, Virasal): Using brush applicator supplied, apply twice to entire wart surface; allow first application to dry before applying second.106 116 Repeat once or twice daily as directed by clinician.106 116 Visible improvement usually occurs during first or second week of therapy with resolution after 4–6 weeks; however, some warts may take longer to resolve.106 116

Hyperkeratotic Skin Disorders (verrucae, ichthyoses vulgaris, palmoplantar keratosis, keratosis pilaris, pityriasis rubra pilaris, psoriasis [including body, scalp, palms, and soles])
Topical

Salicylic acid 6% cream or lotion: Hydrate affected area of skin (e.g., with wet packs or baths) for ≥5 minutes prior to application.117 Apply topically to affected area(s) at bedtime and occlude.117 Wash off in the morning; may apply a bland cream or lotion if affected skin is irritated or excessively dry.117 In areas where occlusion is not possible, apply more frequently.117 However, excessive, repeated application does not necessarily increase therapeutic benefit and may increase risk of adverse local effects and salicylism.117 (See Salicylate Toxicity under Cautions.)

Cautions for Salicylic Acid

Contraindications

  • Known sensitivity to salicylic acid or any other ingredient in the formulation.117

  • Salicylic acid 27.5 and 28.5% solutions: Patients with diabetes or impaired circulation; use on moles, birthmarks, and unusual warts with hair growing from them, or warts on the face.106 116

Warnings/Precautions

Warnings

Because salicylic acid is rapidly and efficiently absorbed percutaneously following topical application to the skin, adverse effects as a result of systemic exposure to the drug are possible.118 120

Salicylate Toxicity

Although risk is minimal with topical use, salicylate toxicity (e.g., nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, psychosis) is possible after prolonged or excessive use over large areas of the body.117 118 120 If salicylic acid toxicity occurs, immediately discontinue; administer fluids to promote urinary excretion, and administer sodium bicarbonate (oral or IV) if clinically necessary.117

Avoid concomitant use of oral aspirin and other salicylate-containing products (e.g., salicylate athletic creams) to minimize exposure to salicylic acid.117 (See Interactions.)

Sensitivity Reactions

Serious Hypersensitivity Reactions

Rare, but serious hypersensitivity reactions (e.g., anaphylaxis, skin irritation, burning, erythema, dermatitis) reported with certain nonprescription (over-the-counter, OTC) topical acne preparations containing salicylic acid or benzoyl peroxide.124 Such events occurred within minutes to 24 hours of use, and sometimes required hospitalization.124 It is not clear whether hypersensitivity was triggered by benzoyl peroxide, salicylic acid, or an inactive ingredient contained in the preparation.124

If any symptoms of a serious hypersensitivity reaction (e.g., hives, itching, throat tightness, difficulty breathing, faintness, swelling of the eyes, face, lips, or tongue) occur, immediately discontinue and avoid future use of the product.124 To reduce risk of serious hypersensitivity reactions, FDA recommends sensitivity testing (e.g., application of a small amount for 3 days) prior to first use of a topical acne preparation.124

General Precautions

Administration Precautions

Consult a clinician prior to initiating self-medication for the control of seborrheic dermatitis or psoriasis if condition covers a large area of the body.103 109

When used for self-medication of seborrheic dermatitis, psoriasis, or dandruff, consult a clinician if condition worsens or does not improve after regular use.103

For external use only; if product gets into eye, flush with water for 15 minutes.100 101 102 103

Topical Effects

Possible excessive erythema or scaling if applied to open skin lesions.117

When applying wart removal preparations, avoid contact with normal skin surrounding wart; local irritation may occur.106 116 Discontinue treatment if excessive irritation occurs.106 116

Concomitant Illnesses

Do not use salicylic acid wart, corn, and callus removal preparations in patients with diabetes or with poor blood circulation.101 107

Specific Populations

Pregnancy

Category C.117

No adequate and well-controlled studies in pregnant women; use during pregnancy only if potential benefits justify possible risks to fetus.117

Lactation

Discontinue nursing or drug.117 If used in nursing women, avoid applying to chest area to avoid contaminating infant.117

Pediatric Use

Because of a greater risk of systemic absorption and toxicity, some experts recommend that salicylic acid be avoided in children.127 Some manufacturers state that use of salicylic acid is contraindicated in pediatric patients <2 years of age.117

Manufacturers of some topical salicylic acid preparations for the treatment of psoriasis or seborrheic dermatitis state that the drug is intended for self-medication in normal healthy adults only; use in pediatric patients <18 years of age should be under the direction of a clinician.109

Salicylates should not be used in children and adolescents with varicella infection or influenza because of an increased risk of developing Reye’s syndrome.117

Hepatic Impairment

Prolonged and repeated topical use over large areas in patients with substantial hepatic impairment may cause salicylate toxicity.117 Limit treatment area and monitor for possible signs of salicylate toxicity in patients with hepatic impairment.117 (See Salicylate Toxicity under Cautions.)

Renal Impairment

Prolonged and repeated topical use over large areas in patients with substantial renal impairment may cause salicylate toxicity.117 Limit treatment area and monitor for possible signs of salicylate toxicity in patients with renal impairment.117 (See Salicylate Toxicity under Cautions.)

Common Adverse Effects

Skin irritation and dryness.100

Interactions for Salicylic Acid

Because salicylic acid is rapidly and efficiently absorbed percutaneously following topical application to the skin, drug interactions as a result of systemic exposure to the drug are possible.118

Topical Acne Preparations

Cumulative irritant or drying effect.100 If irritation occurs, use only one topical acne medication at a time.100

Protein-bound Drugs

Potential for salicylate to displace or to be displaced by other protein-bound drugs.117

Specific Drugs

Drug

Interaction

Comments

Acidifying agents

Potential increased plasma salicylate concentrations117

Alkalinizing agents

Potential decreased plasma salicylate concentrations117

Anticoagulants (warfarin, heparin)

Increased risk of bleeding117 118

Salicylates decrease platelet adhesiveness and may potentially interfere with the effects of heparin117

Antidiabetic agents (sulfonylureas)

Potential for increased hypoglycemic effect because of displacement of sulfonylureas from protein binding sites117

Aspirin or other salicylate-containing drugs

Increased risk of salicylate toxicity117

Caution advised; if possible, use alternative NSAIA that is not salicylate-based117

Corticosteroids

Potential decreased plasma salicylate concentrations117

Potential increased plasma salicylate concentrations and salicylate toxicity when corticosteroids are discontinued117

Diuretics

Possible increased plasma salicylate concentrations due to contracted extracellular space117

Methotrexate

Possible increased methotrexate toxicity because of displacement from protein binding sites117

Pyrazinamide

Possible prevention or reduction of hyperuricemic effects117

Uricosuric agents (e.g., probenecid, sulfinpyrazone)

Reduced uricosuric effect117

Salicylic Acid Pharmacokinetics

Absorption

Bioavailability

Rapidly and well absorbed percutaneously following topical application.117 118

Bioavailability of topical salicylic acid varies according to duration of contact and vehicle.118 120 Absorption has ranged from 9 to >60%.117 118 Following topical application of salicylic acid 6% gel with occlusion, >60% absorbed, with peak plasma concentrations usually attained within 5 hours.117

Plasma Concentrations

Following topical application of salicylic acid 6% gel, peak serum salicylate concentrations were <50 mcg/mL; concentrations >300 mcg/mL generally associated with salicylate toxicity.117

Distribution

Extent

Distributed into extracellular space.117

Plasma Protein Binding

50–80%.117

Special Populations

Patients with a contracted extracellular space secondary to dehydration or diuretics may have increased plasma salicylate levels.117

Elimination

Elimination Route

Excreted principally in urine as salicyluric acid (52%), salicylate glucuronides (42%), and free salicylic acid (6%).117

Stability

Storage

Topical

Tightly closed containers at room temperature.106 116 117 Do not freeze.117

Preparations in flexible collodion are flammable; keep away from heat and open flame.101 102 107 110 111

Actions

  • Topical keratolytic agent that produces desquamation of the horny layer (stratum corneum) of skin by dissolving the intercellular cement that holds epithelial cells together.117 118 120

  • Exact mechanism(s) of action in the treatment of warts not elucidated; keratolytic activity may result in mechanical removal of epidermal cells infected with wart viruses.106 116

  • In low concentrations, has keratoplastic activity (correction of abnormal keratinization); at concentrations ≥1%, has keratolytic activity (causes peeling of skin); and at concentrations ≥20%, has a caustic effect.a

  • Has weak antifungal and antibacterial activity.a

Advice to Patients

  • Importance of keeping salicylic acid preparations out of reach of children.104 105 107

  • Importance of avoiding heat or flames during use of certain salicylic acid collodion formulations.107

  • For external use only.101 102 103 Importance of avoiding contact with eyes.101 102 103

  • Advise patients that salicylic acid topical preparations used concurrently with other topical acne medications may increase skin dryness or irritation.100

  • When used for self-medication of dandruff, seborrheic dermatitis, or psoriasis, importance of consulting a clinician if the condition worsens or does not improve after regular use.103 109

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.117

  • Importance of patients informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs.117

  • Importance of informing patients of other important precautionary information.117 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Salicylic Acid

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder*

Topical

Cake

1%

Proactiv Cleansing Bar

Rodan and Fields

Cleansing Cream

0.5%

Ambi Even & Clear Exfoliating Wash

Valeant

1%

ClarityMD Deep Pore Cleanser

Envy Medical

2%

Aveeno Clear Complexion Cream Cleanser

Johnson and Johnson

Clearasil Daily Clear Oil-free Daily Face Wash

Reckitt Benckiser

Clearasil Ultra Rapid Action Daily Face Wash

Reckitt Benckiser

Cleansing Gel

2%

Clearasil Ultra Rapid Action Daily Gel Wash

Reckitt Benckiser

Cleansing Pledgets (saturated with solution)

0.5%

AcneFree 2-in-1 Acne Wipes

Valeant

Aveeno Clear Complexion Daily Cleansing Pads

Johnson and Johnson

Stridex Sensitive Pads

Blistex

1%

Stridex Essential Pads

Blistex

2%

ClarityMD Acne Treatment Pads

Envy Medical

Clearasil Daily Clear Daily Pore Cleansing Pads

Reckitt Benckiser

Clearasil Ultra On-The-Go Rapid Action Wipes

Reckitt Benckiser

Clearasil Ultra Rapid Action Pads

Reckitt Benckiser

Neutrogena Rapid Clear Treatment Pads

Neutrogena

Noxzema Ultimate Clear Anti-Blemish Pads

Unilever

Oxy Rapid Treatment 3-in-1 Pads

Mentholatum

Oxy Skin Clearing Cleansing Pads

Mentholatum

Stridex Maximum Pads

Blistex

Cleansing Solution

2%

Neutrogena Oil-Free Acne Wash

Neutrogena

Oxy Skin Clearing Cleanser

Mentholatum

Proactiv Deep Cleansing Wash

Rodan and Fields

Cleansing Suspension

0.5%

Clean and Clear Blackhead Erasing Cleanser Mask

Johnson and Johnson

Neutrogena Blackhead Eliminating Cleanser Mask

Neutrogena

1%

Noxzema Ultimate Clear Anti-Blemish Daily Scrub

Unilever

2%

Clearasil Daily Clear Daily Facial Scrub

Reckitt Benckiser

Clearasil Ultra Rapid Action Face Scrub

Reckitt Benckiser

Neutrogena Blackhead Eliminating Daily Scrub

Neutrogena

Neutrogena Oil-Free Acne Wash Daily Scrub

Neutrogena

Oxy Blackhead Removing Scrub

Mentholatum

Cream

3%

MG217 Medicated Salicylic Cream

Lake Consumer Products

6%*

Salex

Coria

Salicylic Acid Cream

Gel

2%

Clearasil Ultra Rapid Action Treatment Gel

Reckitt Benckiser

Neutrogena Rapid Clear Acne Eliminating Spot Gel

Neutrogena

3%

Dermarest Psoriasis Medicated Treatment Gel

Prestige

Keralyt Gel

Summers

5%

Keralyt 5 Gel

Summers

6%*

Keralyt Gel

Summers

Salicylic Acid Gel

17%

Compound W Gel

Prestige

Hydrisalic

Pedinol Pharmacal

Sal-Plant Gel

Pedinol Pharmacal

Lotion

0.5%

Aveeno Clear Complexion Daily Moisturizer

Johnson and Johnson

Clean and Clear Acne Control Moisturizer

Johnson and Johnson

Proactiv Advanced Daily Oil Control

Rodan and Fields

1%

AcneFree Drying Lotion

Valeant

ClarityMD Clarifying Serum

Envy Medical

2%

Clearasil Ultra Rapid Action Treatment Lotion

Reckitt Benckiser

Dermarest Psoriasis Medicated Moisturizer

Prestige

Sebasorb

Summers

6%*

Salex

Coria

Salicylic Acid Cream

Plaster

40%*

Compound W One Step Invisible Strips

Prestige

Compound W One Step Plantar Foot Pads

Prestige

Compound W One Step Pads

Prestige

Curad Mediplast

Medline

Dr. Scholl’s Clear Away One-Step Clear Strips

Bayer

Dr. Scholl’s Clear Away Plantar Wart Remover

Bayer

Dr. Scholl’s Clear Away Wart Remover Ultra-thin Discs

Bayer

Dr. Scholl’s One-Step Corn Remover

Bayer

Paraid One Step Wart Removal Strips

Mcure Health Solutions

Salicylic Acid Plaster

Shampoo

3%

Denorex Extra Strength Dandruff Shampoo and Conditioner

Ultimark Products

Dermarest Psoriasis Medicated Shampoo Plus Conditioner

Prestige

DHS Sal Shampoo

Person & Covey

Neutrogena T/Sal Therapeutic Shampoo

Neutrogena

Psoriasin Therapeutic Shampoo & Body Wash

Alva-Amco Pharmacal

5%

Keralyt 5 Shampoo

Summers

6%

Salex

Coria

Solution

16.7%

Gordofilm Wart Remover

Gordon

17%

Compound W Liquid

Prestige

Dr. Scholl’s Clear Away Fast Acting Liquid

Bayer

Dr. Scholl’s Liquid Corn/Callus Remover

Bayer

DuoFilm Wart Remover

MSD Consumer Care

Salactic Film

Pedinol Pharmacal

27.5%*

Salicylic Acid 27.5% Wart Remover

Virasal

Elorac

Solution, extended-release

28.5%

UltraSal-ER

Elorac

Salicylic Acid Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Ointment

5% with Urea 10%

Kerasal Foot Ointment

Moberg Pharma

AHFS DI Essentials. © Copyright, 2016, American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814. Review Date: September 06, 2016.

References

100. Department of Health and Human Services, Food and Drug Administration. Part 333---Topical antimicrobial drug products for over-the-counter human use. Subpart D---Topical acne drug products. (21 CFR Ch. 1 (Current as of 10-30-15.)) 2015. From Electronic Code of Federal Regulations website.

101. Department of Health and Human Services, Food and Drug Administration. Part 358---Miscellaneous external drug products for over-the-counter human use. Subpart B---Wart remover drug products. (21 CFR Ch. 1 (Current as of 10-30-15.)) 2015. From Electronic Code of Federal Regulations website.

102. Department of Health and Human Services, Food and Drug Administration. Part 358---Miscellaneous external drug products for over-the-counter human use. Subpart F---Corn and callus remover drug products. (21 CFR Ch. 1 Current as of 10-30-15.)) 2015.

103. Department of Health and Human Services, Food and Drug Administration. Part 358---Miscellaneous external drug products for over-the-counter human use. Subpart H---Drug products for the control of dandruff, seborrheic dermatitis, and psoriasis. (21 CFR Ch. 1 (Current as of 10-30-15.)) 2015.

104. Unilever. Noxzema Ultimate Clear Anti-Blemish Daily Scrub (salicylic acid 1%) product information. Trumbull, CT. 2012 Oct.

105. Rodan and Fields. Proactiv cleaning bar (salicylic acid 1%) product information. San Francisco, CA. 2010 Sep.

106. Elorac. UltraSal-ER (28.5% Salicylic Acid Extended Release) antiviral film-forming solution) prescribing information. Vernon Hills, IL; 2014 Jan.

107. Prestige. Compound W Fast Acting Wart Removal Gel (salicylic acid 17%) product information. Tarrytown, NY. Undated.

108. Moberg Pharma. KerasalExfoliating Moisturizer Foot Therapy (salicylic acid 5% and urea 10%) product information. Undated.

109. Alva-Amco Pharmacal. Psoriasin Therapeutic Shampoo and Body Wash (salicylic acid 3%) product information. Niles, IL. 2010 May.

110. Pedinol Pharmacal. Hydrisalic gel (salicylic acid 17%) product information. Farmingdale, NY; 2014 Nov.

111. Prestige. Compound W Fast Acting Liquid (salicylic acid 17%) product information. Tarrytown, NY. Undated.

112. Medline Industries. Mediplast Corn, Callus, and Wart Remover (salicylic acid 40% ) plaster product information. Mundelein, IL. 2012 Nov.

113. Blistex. Stridex Essential (salicylic acid 1%) pads product information. Oak Brook, IL. 2013 Dec.

114. Neutrogena Coporation. Neutrogena Rapid Clear Acne Eliminating Spot Gel (salicylic acid 2%) product information. Los Angeles, CA. 2015 May.

115. Rodan and Fields. Proactiv Advanced Daily Oil Control (salicylic acid 0.5%) product information. San Francisco, CA. 2012 Aug.

116. Elorac. Virasal (salicylic acid 27.5%) antiviral film-forming vehicle product information. Vernon Hills, IL. 2011 Jan.

117. Coria Laboratories. Salex (salicylic acid 6%) cream and lotion prescribing information. Fort Worth, TX; 2013 July.

118. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003; 4:473-92. [PubMed 12814337]

119. Eichenfield LF, Krakowski AC, Piggott C et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013; 131 Suppl 3:S163-86. [PubMed 23637225]

120. Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations. J Am Acad Dermatol. 2014; 70:788-92. [PubMed 24472429]

121. Mason AR, Mason J, Cork M et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013; 3:CD005028. [PubMed 23543539]

122. Kwok CS, Gibbs S, Bennett C et al. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012; 9:CD001781. [PubMed 22972052]

123. Dall'oglio F, D'Amico V, Nasca MR et al. Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2012; 13:73-96. [PubMed 22292461]

124. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of rare but serious hypersensitivity reactions with certain over-the-counter topical acne products. Rockville, MD; 2014 Jun 25. From FDA website. Accessed 2015 Jul 30.

125. Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012; 86:734-40. [PubMed 23062156]

126. Shalita AR. Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clin Ther. 1989 Mar-Apr; 11:264-7. [PubMed 2525420]

127. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009; 60:643-59. [PubMed 19217694]

a. AHFS Drug Information 2016. McEvoy GK, ed. Salicylic Acid. Bethesda, MD: American Society of Health-System Pharmacists; 2016:3545-6.

Hide